Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Takeda Pharmaceutical Company Limited”

1,022 pharma patents match "Takeda Pharmaceutical Company Limited" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 1,022
Index total 30,257
Page 3 / 43

Quick answer

This filtered view shows 1,022 pharmaceutical patents matching "Takeda Pharmaceutical Company Limited" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

1,022 results for “Takeda Pharmaceutical Company Limited” · 30,257 patents in full index Clear search

  1. US 12202797

    Method for producing pyrrole compound

    Takeda Pharmaceutical Company Limited · Granted Jan 21, 2025 · Expires Jan 16, 2045

    granted
  2. US 12202901

    Cannabinoid receptor type 1 (CB1) antibodies, encoding nucleic acid molecules thereof and methods of use thereof

    Takeda Pharmaceutical Company Limited · Granted Jan 21, 2025 · Expires Jan 16, 2045

    granted
  3. US 12202832

    Heterocyclic compounds having a calcium-sensing receptor antagonistic activity

    Takeda Pharmaceutical Company Limited · Granted Jan 21, 2025 · Expires Jan 16, 2045

    granted
  4. US 12186313

    Pyridazinone compounds and their use as DAAO inhibitors

    Takeda Pharmaceutical Company Limited · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  5. US 12188948

    Metabolite biomarkers for diseases associated with the contact activation system

    Takeda Pharmaceutical Company Limited · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  6. US 12178981

    Drug administration method

    Takeda Pharmaceutical Company Limited · Granted Dec 31, 2024 · Expires Dec 26, 2044

    granted
  7. US 12178861

    Stabilized liquid and lyophilized ADAMTS13 formulations

    Takeda Pharmaceutical Company Limited · Granted Dec 31, 2024 · Expires Dec 26, 2044

    granted
  8. US 12171832

    Methods of treating ulcerative colitis

    Takeda Pharmaceutical Company Limited · Granted Dec 24, 2024 · Expires Dec 19, 2044

    granted
  9. US 12171777

    Methods of making a cyclic dinucleotide

    Takeda Pharmaceutical Company Limited · Granted Dec 24, 2024 · Expires Dec 19, 2044

    granted
  10. US 12168041

    Methods and compositions for CNS delivery of arylsulfatase A

    Takeda Pharmaceutical Company Limited · Granted Dec 17, 2024 · Expires Dec 12, 2044

    granted
  11. US 12161702

    Methods and compositions for CNS delivery of heparan N-sulfatase

    Takeda Pharmaceutical Company Limited · Granted Dec 10, 2024 · Expires Dec 5, 2044

    granted
  12. US 12162864

    Condensed-cyclic compound

    Takeda Pharmaceutical Company Limited · Granted Dec 10, 2024 · Expires Dec 5, 2044

    granted
  13. US 12156903

    Use of ADAMTS13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome

    Takeda Pharmaceutical Company Limited · Granted Dec 3, 2024 · Expires Nov 28, 2044

    granted
  14. US 12152027

    Heterocyclic compound

    Takeda Pharmaceutical Company Limited · Granted Nov 26, 2024 · Expires Nov 21, 2044

    granted
  15. US 12144809

    Treatment of prostate cancer

    Takeda Pharmaceutical Company Limited · Granted Nov 19, 2024 · Expires Nov 14, 2044

    granted
  16. US 12128090

    Methods of prophylactic treatment using recombinant VWF (rVWF)

    Takeda Pharmaceutical Company Limited · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  17. US 12128102

    Constrained conditionally activated binding proteins

    Takeda Pharmaceutical Company Limited · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  18. US 12122815

    GIP receptor agonist peptide compounds and uses thereof

    Takeda Pharmaceutical Company Limited · Granted Oct 22, 2024 · Expires Oct 17, 2044

    granted
  19. US 12121569

    Methods and compositions for CNS delivery of iduronate-2-sulfatase

    Takeda Pharmaceutical Company Limited · Granted Oct 22, 2024 · Expires Oct 17, 2044

    granted
  20. US 12110343

    Anti-plasma kallikrein antibodies

    Takeda Pharmaceutical Company Limited · Granted Oct 8, 2024 · Expires Oct 3, 2044

    granted
  21. US 12097199

    Administration of SUMO-activating enzyme inhibitor and anti-CD20 antibodies

    Takeda Pharmaceutical Company Limited · Granted Sep 24, 2024 · Expires Sep 19, 2044

    granted
  22. US 12097306

    Conformal coating of biological surfaces

    Takeda Pharmaceutical Company Limited · Granted Sep 24, 2024 · Expires Sep 19, 2044

    granted
  23. US 12097198

    Treatment of prostate cancer

    Takeda Pharmaceutical Company Limited · Granted Sep 24, 2024 · Expires Sep 19, 2044

    granted
  24. US 12091410

    Heterocyclic compound

    Takeda Pharmaceutical Company Limited · Granted Sep 17, 2024 · Expires Sep 12, 2044

    granted